Key eligibility criteria included EGFR and ALK clinically actionable mutation-negative, immune checkpoint inhibitor-naive and chemotherapy-naive metastatic NSCLC with a PD-L1 expression level of ≥1% (Methods). Here, EGFR is linked to non-small cell lung carcinoma.